Zafgen Insists Life For Beloranib After Patient Death
This article was originally published in Scrip
Zafgen Inc. officials on Oct. 16 did their best to try to assure investors and analysts after the FDA slapped a partial hold on the company's Phase III bestPWS (ZAF-311) trial testing its experimental severe obesity drug beloranib following the death of one of the study participants taking the medicine – with the CEO even declaring the adverse outcome was "not an unexpected finding," given the firm anticipated one to two deaths would occur.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.